Press releases

20 April, 2018

Regulatory

NeuroVive’s Board Members, Senior Executives and employees will subscribe units in the ongoing rights issue

In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 191,200 units equivalent to MSEK 1.5. The subscription period in [&hellip ...

18 April, 2018

Regulatory

NeuroVive’s KL1333 receives FDA Orphan Drug Designation for treatment of mitochondrial diseases

Lund, Sweden, 18 April 2018 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Drug Designation by t ...

17 April, 2018

NeuroVive’s partner Yungjin Pharm completes KL1333 Phase I study recruitment

Lund, Sweden, 17 April 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the last vi ...

9 April, 2018

Regulatory

NeuroVive publishes prospectus in connection with preferential rights issue

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF ...

26 March, 2018

Regulatory

NeuroVive Pharmaceutical AB publishes 2017 Annual report

Lund, Sweden, 26 March, 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2017 is now available on the company's ...

26 March, 2018

Regulatory

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Friday, April 27, 2017, at 10 am at Medicon Village, Scheelevä ...

22 March, 2018

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 22 March 2018, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company"). A summary of the resolutions follows. All resolutions were passed ...

16 March, 2018

NeuroVive to present at 2nd Annual H.C. Wainwright NASH Investor Conference

Lund, Sweden, 16 March 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that its Chief Medical Officer Magnus Hansson will present the company's non-alcoholic st ...

6 March, 2018

NeuroVive presents at the Stockholm Corporate Finance Life Science Seminar

Lund, Sweden, 6 March 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) participates in the Stockholm Corporate Finance Life Science Seminar at Operaterassen on 7 March 2018 at 1 ...

20 February, 2018

Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2017

Strong trend for mitochondrial disorder projects

15 February, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 2 pm on Thursday 22 March 2018 at Medicon Village, Scheelevägen 2 ...

15 February, 2018

Regulatory

NeuroVive decides on a Rights issue for continued drug development

Lund, Sweden, 15 February 2018, NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "th ...